ATE470454T1 - Multimere konstrukte - Google Patents

Multimere konstrukte

Info

Publication number
ATE470454T1
ATE470454T1 AT05810409T AT05810409T ATE470454T1 AT E470454 T1 ATE470454 T1 AT E470454T1 AT 05810409 T AT05810409 T AT 05810409T AT 05810409 T AT05810409 T AT 05810409T AT E470454 T1 ATE470454 T1 AT E470454T1
Authority
AT
Austria
Prior art keywords
fusion proteins
domain
flt
multimerization
neovascularization
Prior art date
Application number
AT05810409T
Other languages
English (en)
Inventor
Abraham Scaria
Peter Pechan
Samuel Wadsworth
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Application granted granted Critical
Publication of ATE470454T1 publication Critical patent/ATE470454T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
AT05810409T 2004-09-13 2005-09-13 Multimere konstrukte ATE470454T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60888704P 2004-09-13 2004-09-13
US65820905P 2005-03-04 2005-03-04
PCT/US2005/032320 WO2006031689A2 (en) 2004-09-13 2005-09-13 Multimeric constructs

Publications (1)

Publication Number Publication Date
ATE470454T1 true ATE470454T1 (de) 2010-06-15

Family

ID=36060586

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05810409T ATE470454T1 (de) 2004-09-13 2005-09-13 Multimere konstrukte

Country Status (15)

Country Link
US (4) US7928072B2 (de)
EP (2) EP2229956B1 (de)
JP (1) JP4944032B2 (de)
CN (1) CN101094688B (de)
AT (1) ATE470454T1 (de)
BR (1) BRPI0515264B1 (de)
CY (1) CY1114155T1 (de)
DE (1) DE602005021811D1 (de)
DK (2) DK2229956T3 (de)
ES (2) ES2407859T3 (de)
IL (2) IL181839A0 (de)
MX (1) MX2007002942A (de)
PL (2) PL2229956T3 (de)
PT (2) PT2229956E (de)
WO (1) WO2006031689A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE470454T1 (de) * 2004-09-13 2010-06-15 Genzyme Corp Multimere konstrukte
EP2203476B1 (de) 2007-09-25 2016-10-26 Genzyme Corporation Zusammensetzungen und verfahren zur inhibierung von interleukinpfaden
BRPI0908496A2 (pt) * 2008-02-20 2019-01-15 Genzyme Corp inibição de angiogênese
WO2010019263A2 (en) * 2008-08-15 2010-02-18 Genzyme Corporation Soluble flt constructs for treating cancers
US8697654B2 (en) * 2008-12-18 2014-04-15 E I Du Pont De Nemours And Company Peptide linkers for effective multivalent peptide binding
DK2601214T3 (en) 2010-08-06 2018-02-05 Genzyme Corp VEGF ANTAGONIST COMPOSITIONS AND APPLICATIONS THEREOF
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
CN107988156B (zh) 2011-06-30 2022-01-04 建新公司 T细胞活化的抑制剂
ES2664224T3 (es) * 2011-08-19 2018-04-18 Children's Medical Center Corporation Proteína de unión a VEGF para el bloqueo de la angiogénesis
CN102399292A (zh) * 2011-09-14 2012-04-04 盛剑鹏 重组干细胞因子与免疫球融合蛋白及其制备
US20130090375A1 (en) * 2011-10-06 2013-04-11 Cornell University Virus-mediated delivery of bevacizumab for therapeutic applications
CA2862485C (en) 2012-01-24 2021-05-11 Inter-K Pty Limited Peptide agents for cancer therapy
EP2844267A4 (de) * 2012-04-25 2016-02-24 Ligacept Llc Erbb-liganden-bindungsmoleküle mit breitem spektrum und verfahren zu deren verwendung
TWI702955B (zh) 2012-05-15 2020-09-01 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒（ａａｖ）ｓｆｌｔ-１治療老年性黃斑部退化（ａｍｄ）
RU2015100656A (ru) * 2012-06-27 2016-08-20 Ф. Хоффманн-Ля Рош Аг Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения
JP6203838B2 (ja) 2012-06-27 2017-09-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 少なくとも２つの異なる結合実体を含む、テーラーメイドの高度に選択的かつ多重特異的なターゲティング実体を選択および作製するための方法、ならびにその使用
LT2968461T (lt) 2013-03-13 2022-12-27 Genzyme Corporation Sulieti baltymai, apimantys pdgf ir vegf surišančius fragmentus, ir jų panaudojimo būdai
KR102049990B1 (ko) 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
RU2703145C2 (ru) * 2014-02-06 2019-10-15 Джензим Корпорейшн Композиции и способы лечения и предотвращения дегенерации желтого пятна
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
GB201412748D0 (en) * 2014-07-17 2014-09-03 Levicept Ltd Therapeutic use of P75NTR neurotrophin binding protein
CN107207603A (zh) * 2015-02-03 2017-09-26 吉安特科技股份有限公司 趋化因子‑免疫球蛋白融合多肽，其组合物、制备方法以及用途
BR112018013407A2 (en) 2015-12-30 2018-12-18 Kodiak Sciences Inc. antibodies and conjugates thereof
KR102205830B1 (ko) * 2017-10-26 2021-01-21 주식회사 큐로진생명과학 솔루블 VEGFR-1 변이체 cDNA를 함유하는 rAAV를 포함하는 황반변성 치료용 조성물
SG11202008242XA (en) 2018-03-02 2020-09-29 Kodiak Sciences Inc Il-6 antibodies and fusion constructs and conjugates thereof
EP3794015A4 (de) 2018-05-15 2022-03-30 InterK Peptide Therapeutics Limited Aktivierungsmittel
CN114805598A (zh) * 2019-04-28 2022-07-29 广州市雷德生物科技有限公司 促进蛋白二聚体形成的拉链扣结构及其应用
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021226444A2 (en) 2020-05-08 2021-11-11 Regeneron Pharmaceuticals, Inc. Vegf traps and mini-traps and methods for treating ocular disorders and cancer
CN116370399A (zh) * 2021-12-31 2023-07-04 康码（上海）生物科技有限公司 用于病毒的防护和/或治疗的膜剂及其应用
CN119677771A (zh) 2022-08-02 2025-03-21 帕诺洛斯生物科技有限公司 经修饰的融合蛋白及其用途

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
EP0325224B1 (de) * 1988-01-22 1996-07-31 ZymoGenetics, Inc. Verfahren zur Herstellung von sekretierten Rezeptoranalogen
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JPH03233530A (ja) * 1990-02-09 1991-10-17 Fuji Photo Optical Co Ltd カメラ
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US20020032313A1 (en) * 1991-03-29 2002-03-14 Genentech, Inc. Vascular endothelial cell growth factor antagonists
EP0666868B2 (de) 1992-10-28 2006-06-14 Genentech, Inc. Verwendung von anti-VEGF Antikörpern zur Behandlung von Krebs
FR2702152B1 (fr) 1993-03-03 1995-05-24 Inst Nat Sante Rech Med Virus recombinants et leur utilisation en thérapie génique.
ATE281469T1 (de) * 1993-03-25 2004-11-15 Merck & Co Inc Inhibitor des wachstumsfaktors für gefäss- endothelzellen
DE69434447T2 (de) 1993-06-07 2006-05-18 Vical, Inc., San Diego Für die gentherapie verwendbare plasmide
US5919676A (en) 1993-06-24 1999-07-06 Advec, Inc. Adenoviral vector system comprising Cre-loxP recombination
US6686200B1 (en) 1993-08-31 2004-02-03 Uab Research Foundation Methods and compositions for the large scale production of recombinant adeno-associated virus
CA2189067A1 (en) 1994-04-28 1995-11-09 Gary J. Nabel Gene delivery vector using plasmid dna packaged into an adenovirus and a packaging cell line
US5827702A (en) 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
US5719131A (en) 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US5747471A (en) 1994-12-09 1998-05-05 Genzyme Corporation Cationic amphiphiles containing steroid lipophilic groups for intracellular delivery of therapeutic molecules
US5948767A (en) 1994-12-09 1999-09-07 Genzyme Corporation Cationic amphiphile/DNA complexes
US5840710A (en) 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US5767099A (en) 1994-12-09 1998-06-16 Genzyme Corporation Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
US5650096A (en) 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5910487A (en) 1994-12-09 1999-06-08 Genzyme Corporation Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
US5939401A (en) 1994-12-09 1999-08-17 Genzyme Corporation Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
ATE243260T1 (de) 1995-04-17 2003-07-15 Univ Texas Adenovirus helfervirus system
ATE445705T1 (de) 1995-06-15 2009-10-15 Crucell Holland Bv Verpackungssysteme für humane rekombinante adenoviren zur gentherapie
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
JPH09154588A (ja) * 1995-10-07 1997-06-17 Toagosei Co Ltd Ｖｅｇｆ結合性ポリペプチド
JP2000503534A (ja) 1996-01-05 2000-03-28 ジェネティック セラピー，インコーポレイテッド アデノウイルスベクターのリコンビナーゼ媒介生成
US5994317A (en) 1996-04-09 1999-11-30 Vical Incorporated Quaternary cytofectins
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US5935936A (en) 1996-06-03 1999-08-10 Genzyme Corporation Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules
AU738806B2 (en) 1996-09-24 2001-09-27 Merck & Co., Inc. Gene therapy for inhibition of angiogenesis
US5861397A (en) 1996-10-03 1999-01-19 Vical Incorporated Piperazine based cytofectins
JP3837748B2 (ja) 1997-01-17 2006-10-25 東亞合成株式会社 Ｖｅｇｆ結合性ポリペプチド
US5925628A (en) 1997-03-31 1999-07-20 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5912239A (en) 1997-04-04 1999-06-15 Genzyme Corporation Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules
US5948925A (en) 1997-05-06 1999-09-07 Genzyme Corporation Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
US5942634A (en) 1997-05-09 1999-08-24 Genzyme Corporation Cationic amphiphiles for cell transfections
EP1173191A4 (de) 1997-05-13 2004-12-01 Univ California Neuartige antiangiogenese peptidagenzien sowie ihre therapeutische und diagnostische verwendung
US5952916A (en) 1998-05-28 1999-09-14 Atras Auto Co., Ltd Hammer-equipped emergency signal device
AU8435698A (en) 1997-06-03 1998-12-21 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Regulatory sequences capable of conferring expression of a heterologous dna sequence in endothelial cells in vivo and uses thereof
EP1009814B1 (de) * 1997-06-18 2007-08-29 Merck & Co., Inc. (a New Jersey corp.) Kdr, ein menschlicher tyrosin kinase rezeptor
US5963622A (en) 1997-07-29 1999-10-05 3Com Corporation Mode signalling method and apparatus
CA2303768C (en) * 1997-09-19 2009-11-24 The Trustees Of The University Of Pennsylvania Methods and vector constructs useful for production of recombinant aav
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
WO1999057296A1 (en) 1998-05-01 1999-11-11 Genzyme Corporation Partially deleted adenoviral vectors
US6378526B1 (en) * 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
US7083950B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
US6472179B2 (en) * 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6943153B1 (en) * 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
EP1183051A2 (de) 1999-03-15 2002-03-06 Chiron Corporation Verwendung von rekombinanten expressionsvektoren zur behandlung oder vorbeugung von augenkrankheiten
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7070959B1 (en) * 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
RS50073B (sr) * 1999-06-08 2009-01-22 Regeneron Pharmaceuticals I.N.C., Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama
US6821775B1 (en) * 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
WO2002024234A2 (en) 2000-09-20 2002-03-28 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
CA2436326C (en) * 2001-01-09 2012-08-14 Merck Patent Gesellschaft Mit Beschraenkter Haftung Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
JP2005500083A (ja) * 2001-01-25 2005-01-06 ヒル−ロム サービシーズ，インコーポレイティド 外科用テーブルのための油圧式アクチュエータ装置
DE10109855A1 (de) * 2001-03-01 2002-09-12 Stanislawski Thomas Polypeptide eines p53-Protein-spezifischen murinen alpha/beta T-Zell Rezeptors, diese kodierende Nukleinsäuren und deren Verwendung
US7078411B2 (en) * 2001-05-16 2006-07-18 Umdnj (Univ Of Medicine & Dentist. Of Nj) Phospholipid transfer protein (PLTP) and cholestoral metabolism
NZ535100A (en) 2002-03-20 2008-04-30 Univ Florida RAAV vector compositions and methods for the treatment of choroidal neovascularization
CU23178A1 (es) * 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
AU2004224123A1 (en) 2003-03-26 2004-10-07 Apogenix Gmbh Treatment of viral infections
ATE470454T1 (de) * 2004-09-13 2010-06-15 Genzyme Corp Multimere konstrukte
BRPI0518105A (pt) 2004-12-17 2008-11-04 Genentech Inc uso de antagonista da angiogênese e uso de anticorpo anti-vegf
WO2010019263A2 (en) 2008-08-15 2010-02-18 Genzyme Corporation Soluble flt constructs for treating cancers

Also Published As

Publication number Publication date
US20140193411A1 (en) 2014-07-10
PT2229956E (pt) 2013-07-31
HK1144663A1 (en) 2011-03-04
CN101094688B (zh) 2013-05-01
US20180155417A1 (en) 2018-06-07
IL216095A0 (en) 2011-12-29
EP2229956B1 (de) 2013-04-24
EP1804835B9 (de) 2010-09-29
CY1114155T1 (el) 2016-08-31
US8658602B2 (en) 2014-02-25
BRPI0515264B1 (pt) 2018-12-18
US20070224178A1 (en) 2007-09-27
US7928072B2 (en) 2011-04-19
ES2347340T3 (es) 2010-10-28
EP1804835B1 (de) 2010-06-09
PL1804835T3 (pl) 2010-11-30
DE602005021811D1 (de) 2010-07-22
EP2229956A1 (de) 2010-09-22
ES2407859T3 (es) 2013-06-14
IL181839A0 (en) 2007-07-04
DK2229956T3 (da) 2013-07-29
JP2008512127A (ja) 2008-04-24
JP4944032B2 (ja) 2012-05-30
PL2229956T3 (pl) 2013-09-30
IL216095A (en) 2013-10-31
US20110268735A1 (en) 2011-11-03
EP1804835A4 (de) 2008-07-30
DK1804835T3 (da) 2010-10-11
WO2006031689A3 (en) 2006-07-06
WO2006031689A2 (en) 2006-03-23
US9815892B2 (en) 2017-11-14
EP1804835A2 (de) 2007-07-11
CN101094688A (zh) 2007-12-26
BRPI0515264A (pt) 2008-07-15
MX2007002942A (es) 2008-03-05
PT1804835E (pt) 2010-10-04

Similar Documents

Publication Publication Date Title
ATE470454T1 (de) Multimere konstrukte
Kirsch et al. Crystal structure of the BMP-2–BRIA ectodomain complex
Aumailley The laminin family
EA202092093A1 (ru) Композиции и способы перепрограммирования tcr с применением слитых белков
ATE475708T1 (de) Fusionskonstrukte und deren verwendung zur produktion von antikörpern mit erhöhter fc rezeptor bindungsaffinität und effektorfunktion
PT2016102E (pt) Recetores de célula t quimérica e materiais relacionados e métodos de uso
CY1122579T1 (el) Βελτιωμενα nanobodies τμ για τη θεραπεια διαταραχων που μεσολαβουνται απο συσσωματωματα
WO2010003766A3 (en) Multimeric tnf receptors
AR062030A1 (es) Proteinas de fusion de exendina
ATE505481T1 (de) Fusionsproteine der tnf-superfamilie
AU2013211824A8 (en) Fusion proteins comprising IgG2 hinge domains
ATE555383T1 (de) Lösliche heterodimere rezeptoren und ihre verwendung
MX350591B (es) Ratones que producen proteinas de union que comprenden dominios vl.
RU2015142999A (ru) Слитые белки, содержащие связывающие части pdgf и vegf, и способы их применения
CY1119774T1 (el) Χρηση πρωτεϊνων εξωκυτταρικου πεδιου του fgfr1 για την αγωγη καρκινων χαρακτηριζομενων απο εξαρτωμενες απο προσδεμα ενεργοποιητικες μεταλλαξεις στο fgfr2
CY1116288T1 (el) Tnfsf απλης αλυσου μορια
MX388059B (es) Composiciones y metodos para modular la comunicacion celular.
MY189467A (en) Antibodies comprising chimeric constant domains
DK1987150T3 (da) Selektion af værtsceller, der udtrykker protein på høje niveauer
DK1532261T3 (da) Fremgangsmåder og DNA-konstrukter til produktion af polypeptider med højt udbytte
WO2010018444A3 (en) An expression vector and a method thereof
Li et al. Recombinant expression, purification and characterization of human soluble tumor necrosis factor receptor 2
ATE466874T1 (de) Mit scytovirin der domäne 1 verwandte polypeptide
Lee et al. De Novo design of a potent Wnt Surrogate specific for the frizzled7 subtype members
WO2024073513A3 (en) Chimeric receptors comprising interleukin 7 receptor (il7r) domains

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1804835

Country of ref document: EP